Capital Investment Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$477K Sell
3,121
-78
-2% -$12K 0.01% 503
2025
Q4
$441K Sell
3,199
-340
-10% -$44.5K 0.01% 503
2025
Q3
$454K Sell
3,539
-355
-9% -$43.3K 0.01% 489
2025
Q2
$471K Sell
3,894
-120
-3% -$13.5K 0.01% 464
2025
Q1
$447K Sell
4,014
-189
-4% -$20.1K 0.01% 451
2024
Q4
$409K Sell
4,203
-22
-0.5% -$2.35K 0.01% 455
2024
Q3
$486K Sell
4,225
-413
-9% -$46.9K 0.01% 410
2024
Q2
$494K Buy
4,638
+122
+3% +$12.2K 0.01% 400
2024
Q1
$437K Buy
4,516
+28
+0.6% +$2.87K 0.01% 415
2023
Q4
$453K Buy
4,488
+354
+9% +$34.2K 0.01% 395
2023
Q3
$421K Sell
4,134
-66
-2% -$6.7K 0.01% 388
2023
Q2
$424K Sell
4,200
-85
-2% -$8.5K 0.01% 364
2023
Q1
$394K Sell
4,285
-1,276
-23% -$111K 0.01% 395
2022
Q4
$504K Sell
5,561
-58
-1% -$4.88K 0.02% 354
2022
Q3
$427K Sell
5,619
-443
-7% -$36.7K 0.01% 359
2022
Q2
$512K Buy
6,062
+274
+5% +$24K 0.02% 342
2022
Q1
$508K Buy
5,788
+17
+0.3% +$1.47K 0.02% 354
2021
Q4
$505K Sell
5,771
-325
-5% -$27K 0.02% 372
2021
Q3
$499K Sell
6,096
-176
-3% -$15.8K 0.02% 363
2021
Q2
$572K Buy
6,272
+101
+2% +$8.99K 0.02% 347
2021
Q1
$527K Sell
6,171
-238
-4% -$21.4K 0.02% 337
2020
Q4
$605K Buy
6,409
+13
+0.2% +$1.14K 0.03% 313
2020
Q3
$556K Hold
6,396
0.03% 303
2020
Q2
$559K Buy
6,396
+12
+0.2% +$1.04K 0.03% 295
2020
Q1
$526K Sell
6,384
-234
-4% -$20.9K 0.03% 274
2019
Q4
$627K Sell
6,618
-185
-3% -$16.6K 0.03% 290
2019
Q3
$591K Buy
6,803
+5
+0.1% +$449 0.03% 285
2019
Q2
$621K Sell
6,798
-710
-9% -$60.1K 0.03% 276
2019
Q1
$647K Sell
7,508
-17
-0.2% -$1.36K 0.04% 262
2018
Q4
$579K Buy
7,525
+963
+15% +$75K 0.04% 263
2018
Q3
$507K Buy
6,562
+45
+0.7% +$3.33K 0.03% 293
2018
Q2
$441K Buy
6,517
+1,072
+20% +$74K 0.03% 318
2018
Q1
$394K Buy
5,445
+1,089
+25% +$82.9K 0.03% 335
2017
Q4
$328K Buy
4,356
+18
+0.4% +$1.36K 0.02% 367
2017
Q3
$334K Sell
4,338
-242
-5% -$18.3K 0.02% 354
2017
Q2
$343K Sell
4,580
-45
-1% -$3.19K 0.02% 348
2017
Q1
$308K Buy
4,625
+162
+4% +$10.8K 0.02% 360
2016
Q4
$291K Sell
4,463
-29
-0.6% -$1.88K 0.02% 355
2016
Q3
$318K Buy
4,492
+41
+0.9% +$2.99K 0.03% 330
2016
Q2
$329K Sell
4,451
-45
-1% -$3.11K 0.03% 313
2016
Q1
$292K Sell
4,496
-61
-1% -$4.15K 0.03% 325
2015
Q4
$351K Sell
4,557
-2
-0% -$159 0.04% 302
2015
Q3
$375K Sell
4,559
-65
-1% -$5.79K 0.04% 267
2015
Q2
$407K Buy
4,624
+308
+7% +$28.3K 0.04% 263
2015
Q1
$381K Sell
4,316
-117
-3% -$10.4K 0.04% 276
2014
Q4
$368K Buy
4,433
+117
+3% +$9.7K 0.04% 279
2014
Q3
$364K Hold
4,316
0.04% 263
2014
Q2
$350K Sell
4,316
-111
-3% -$8.73K 0.04% 281
2014
Q1
$337K Buy
4,427
+32
+0.7% +$2.33K 0.04% 284
2013
Q4
$317K Buy
+4,395
New +$306K 0.04% 283

Other funds holding NVS

Capital Investment Advisors's NVS Position: Q1 2026 in Review

Capital Investment Advisors reduced its Novartis (NVS) stake by 2.4% in Q1 2026, selling an estimated $12K and leaving 3,121 shares worth $477K. The position accounts for 0.01% of the portfolio, ranked #503.

Capital Investment Advisors first reported a position in NVS in Q4 2013 and has held it in 50 quarters since. The position peaked at $647K in Q1 2019. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Capital Investment Advisors held 3,121 shares of Novartis worth $477K as of Q1 2026.
  • Capital Investment Advisors sold 78 Novartis shares in Q1 2026, an estimated $12K.
  • Novartis made up 0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #503 holding.
  • Capital Investment Advisors first reported a position in Novartis in Q4 2013 and has held it in 50 quarters since.
  • Capital Investment Advisors's Novartis position peaked at $647K in Q1 2019.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.